Axolotl Biologix
Phillip W. Larson, President

Headquartered in Phoenix, Arizona, Axolotl Biologix is focused on researching to optimize the use of human biologicals and to develop biological-related products that will foster regeneration and healing for many conditions that affect patients. These conditions include orthopedic, wound care, pain management, ophthalmic, cardiovascular, cosmetic, and more. Axolotl is currently negotiating partnerships with leading universities and research hospitals to find ways to improve current technologies and procedures to improve patients’ quality of life.  Much of our future development efforts and intellectual property are based in a recombinant elastomeric protein called tropoelastin, which is the precursor to elastin.